The risk of hemorrhage in infants with severe coagulopathies unresponsive to fresh frozen plasma (FFP) infusions may preclude therapeutic invasive interventional procedures. We describe the successful use of recombinant factor VIIa (rFVIIa) in two such infants, the first with cirrhosis requiring paracentesis and the second with necrotizing enterocolitis requiring laparotomy. This report reviews the current concepts on the mechanism of action of the drug rFVIIa and considers its expanded use in infants unresponsive to FFP replacement.
INTRODUCTION
Management of severe coagulopathies in infant patients can be challenging requiring alternative therapies if fresh frozen plasma (FFP) or platelet products are of limited use or contraindicated. We report the use of recombinant factor VIIa (rFVIIa) in two such infants. For both of these patients, we used rFVIIa, which is commercially available and has been shown to be of therapeutic value in hemophiliacs with inhibitors. [1] [2] [3] Its hemostatic benefit in bleeding prophylaxis for hemophilic patients is clear. 4, 5 More recently the use of rFVIIa was extended to other bleeding conditions, that is, cirrhotic patients with perioperative coagulopathies and/or life-threatening hemorrhagic conditions unresponsive to FFP, to platelet concentrates, or to prothrombin complex concentrates. 6 Although few studies investigate the risk of thrombosis using rFVIIa in the neonatal population, recent reports in older children and in infants suggest its potential side effect to be minimal. 7, 8 CASE PRESENTATION Case #1 Baby boy O was born at full term by spontaneous vaginal delivery. At 13 days of age, he presented to an emergency room with fever. To start antibiotic therapy, intravenous access was placed, which triggered abnormal bleeding. Evaluation of the bleeding revealed a platelet count of 19,000/ml and a coagulopathy with a prothrombin time (PT) of 55 seconds, and a partial thromboplastin time (aPTT) greater than 100 seconds. Additionally blood was positive, both by serology and by PCR, for Herpes Simplex Virus. A 39-day course of acyclovir was administered. He remained severely coagulopathic with signs of liver failure and ascites. He was then transferred to our medical tertiary care center for liver transplant evaluation. Direct bilirubin was 9 mg/dl, albumin 2.9 g/dl, alkaline phosphatase was elevated to 1305 UI/l, and aspartate and alanine amino transferases were elevated to 98 and 78 UI/l, respectively. A paracentesis was indicated but was problematic due to the coagulopathy, which could not be efficiently corrected through FFP transfusion. Total plasma exchange was not feasible, because this infant's blood volume was insufficient to prime the apheresis machine. As an alternative, one low dose of 40 mg/kg (instead of the usual dose of 90 to 120 mg/kg) of rFVIIa was infused in a 0.4 ml physiologic saline suspension (600 mg/ml). The PT corrected from 49.7 to 19.1 seconds. The international ratio (INR) corrected from 12.4 to 2.0. Subsequently, the patient underwent paracentesis without complications.
Case #2
Baby girl BC was born by cesarean section at 33 weeks of a monoamniotic-monochorionic-twin gestation complicated by growth discordance. At birth, her twin sister weighed 2.34 kg and had a hematocrit of 46.7%. Baby girl BC weighed 1.88 kg and had a hematocrit of 42.2%. On day 4 the abdomen was distended, frank bloody stools were noted and she became coagulopathic (PT: 31.1 seconds and INR: 4.48), acidotic and ventilator dependent. She underwent an exploratory laparotomy, which revealed total colonic necrosis requiring total abdominal colectomy. She received 115 cc/ kg of packed red blood cells, 90 cc/kg of FFP and 70 cc/kg of crystalloid. The patient's worsening coagulopathy was aggravated by hemolysis. T antigen activation study was positive for Tk activation, which contraindicated plasma products. In order to correct the coagulopathy, the patient received one dose of 40 mg/kg of rFVIIa, correcting the PT from 30.7 to 14.9 seconds and the INR from 4.38 to 1.24. Despite the administration of a second dose of 40 mg/kg 12 hours later and aggressive pressor support, the patient remained acidotic and subsequently expired.
DISCUSSION
The use of rFVIIa was successful in the clinical scenarios reported. Rapid correction of the INR prior to a therapeutic paracentesis was achieved in the first patient with end-stage liver disease. In the second patient in whom plasma products were contraindicated because of the presence of Tk polyagglutination, rFVIIa promptly corrected the PT and the INR. Neither infant had evidence of a spontaneous thrombotic event or hemorrhage.
Concern for increased risk of a thromboembolic event has tempered the use of rFVIIa. Infused rFVIIa is not proteolytically active by itself and must have tissue factor (TF) and/or activated platelets present to activate factor X (FX) in two ways. First, rFVIIa forms a complex with TF; the FVIIa/TF complex activates FX and leads to platelet and cofactor activation. 9 Secondly, rFVIIa, infused at high doses, binds directly, albeit weakly, to the surface of activated platelets. On the platelet surface, rFVIIa converts FX to activated FX (FXa) in the absence of TF. 9 FXa remains on the platelet surface where it binds activated factor V and generates small but sufficient amounts of thrombin to initiate localized fibrin clot formation at the site of endothelial cell injury. Since high-dose rFVIIa only activates FX on activated platelets and not on resting platelets, the reaction is localized to the site of injury, minimizing the risk of thromboembolic event. Lisman et al. 9 describe the mechanism of action of rFVIIa as a TF-dependent pathway combined with a TF-independent pathway requiring activated platelet surfaces. Both mechanisms of action lead to thrombin generation localized at the site of an injury.
Although localized hemostasis may result from rFVIIa administration, the associated risk of thromboembolism is still a concern. In the adult population, Aledort 10 reported three cases of myocardial infarcts following rVIIa. In pediatric patients rFVIIa has been used mainly in children with hemophilia, but infrequently in pediatric patients with other coagulopathies. 7, 8, 11 Therefore, the risk of rFVIIa in infants and other nonhemophilic patients is unknown.
Finding the lowest effective dose to minimize side effects is crucial. The dose of rFVIIa given to our patients was 40 mg/kg. This dose is low relative to the standard 90 to 120 mg/kg recommended for hemophilic patients. In the study by Griesen et al., 7 the PT and INR of preterm neonates with coagulopathy unresponsive to plasma products corrected with doses of rFVIIa approaching 80 mg/kg without recognized thrombotic complications. 7 Chuansumrit et al. 11 used a dose of 40 mg/kg and achieved a dramatic response in a preterm infant with umbilical artery laceration.
To complicate dosing decisions, infants have increased clearance of rFVIIa and therefore require a decreased dosing interval in comparison to adults. 8 Adults have correction of their PT and INR following a dose of rFVIIa that lasts about 6 hours. 12 The effect in infants is reported to dissipate in about 3 hours. 8 Long-term therapy for infants requires frequent repetitive dosing and is expensive, with a cost per dose varying from $1000 to 3000. Therefore rFVIIa is more commonly given for acute, active bleeding, or to correct a coagulopathy prior to a surgical procedure, rather than for long-term therapy.
Neither of the patients presented had evidence of thrombosis either clinically or, for the second patient, by autopsy. The use of rFVIIa appears to be an effective alternative therapy in infants for the treatment of severe coagulopathies unresponsive to standard care.
